We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
-1.53%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$310M
AUM Growth
+$31.2M
(+11%)
Cap. Flow
+$36.9M
Cap. Flow
% of AUM
11.89%
Top 10 Holdings %
Top 10 Hldgs %
90.45%
Holding
17
New
1
Increased
10
Reduced
4
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
|
+$10.9M |
| 2 |
Merck
MRK
|
+$8.39M |
| 3 |
Gilead Sciences
GILD
|
+$8.23M |
| 4 |
Orthofix Medical
OFIX
|
+$1.92M |
| 5 |
Enanta Pharmaceuticals
ENTA
|
+$1.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$9.83M |
| 2 |
United Therapeutics
UTHR
|
+$5.48M |
| 3 |
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
|
+$4.63M |
| 4 |
STRR
Star Equity Holdings
STRR
|
+$785K |
| 5 |
JNP
Juniper Pharmaceuticals, Inc. Common Stock
JNP
|
+$241K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$162B
| $36.5M | 11.76% |
537,021
+117,021
| +28% | +$8.23M |
|
|
2
Enanta Pharmaceuticals
ENTA
$366M
| $33.8M | 10.91% |
1,098,524
+42,805
| +4% | +$1.33M |
|
|
3
United Therapeutics
UTHR
$25.8B
| $31.8M | 10.25% |
234,743
-36,166
| -13% | -$5.48M |
|
|
SCMP
4
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
| $30.8M | 9.94% |
2,803,138
+939,383
| +50% | +$10.9M |
|
|
5
Orthofix Medical
OFIX
$477M
| $26.6M | 8.58% |
697,378
+51,848
| +8% | +$1.92M |
|
|
6
Merck
MRK
$322B
| $24.5M | 7.88% |
403,277
+138,265
| +52% | +$8.39M |
|
|
AVNS
7
DELISTED
Avanos Medical
AVNS
| $22.3M | 7.18% |
584,564
+19,772
| +4% | +$770K |
|
|
SRGA
8
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $17.8M | 5.73% |
147,965
+7,400
| +5% | +$770K |
|
9
CONMED
CNMD
$1.39B
| $15.8M | 5.1% |
356,304
+27,627
| +8% | +$1.19M |
|
|
IVC
10
DELISTED
Invacare Corporation
IVC
| $13.7M | 4.42% |
1,150,629
+48,043
| +4% | +$576K |
|
|
11
Amgen
AMGN
$208B
| $11.2M | 3.6% |
68,015
-59,142
| -47% | -$9.83M |
|
|
VXRT
12
DELISTED
Vaxart
VXRT
| $1.85M | 0.6% |
257,848
+8,975
| +4% | +$91.8K |
|
|
STRR
13
DELISTED
Star Equity Holdings
STRR
| $1.77M | 0.57% |
6,684
-3,044
| -31% | -$785K |
|
|
JNP
14
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $1.16M | 0.37% |
243,128
-47,725
| -16% | -$241K |
|
|
DSCI
15
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| – | – |
-891,026
| Closed | -$4.63M |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q1 2017 Portfolio in Review
As of Q1 2017, Krensavage Asset Management held 17 positions worth $310M, up 11% from $279M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Krensavage Asset Management deployed $36.9M of net new capital in Q1 2017, opening 1 new position and adding to 10 existing holdings.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 80% a quarter earlier.
On the sell side, the largest reduction was Amgen, an estimated $9.83M trimmed.
- Krensavage Asset Management added most to Sucampo Pharmaceuticals, Inc. in Q1 2017, an estimated $10.9M increase.
- Krensavage Asset Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $9.83M.
- Krensavage Asset Management fully exited Derma Sciences, Inc. Common Stock (DE) in Q1 2017, selling an estimated $4.63M.
- Krensavage Asset Management's ten largest holdings make up 90% of its $310M portfolio in Q1 2017.
- Krensavage Asset Management opened 1 new position and closed 2 in Q1 2017.
- Krensavage Asset Management's portfolio value rose 11% quarter-over-quarter to $310M.
Based on Krensavage Asset Management's 13F filing for Q1 2017, filed 15 May 2017.